Search
Search
Close this search box.

US Court of Appeals says descheduling cannabis is up to Congress

NO RATIONAL BASIS

US Court of Appeals says descheduling cannabis is up to Congress

In the case ‘United States of America v. Green’, the defendants argued that cannabis’s scheduling in the US Controlled Substances Act “has no rational basis because cannabis does not meet the statutory criteria for inclusion on Schedule I”, reports Benzinga.

The judges however ruled that the argument is insufficient to compel the Court to determine that cannabis’ Schedule I status is unconstitutional. 

“Because there are other plausible considerations that could have motivated Congress’s scheduling of marijuana, we conclude that its classification does not violate the [plaintiffs’] due process or equal protection rights.” 


Enjoy Cannabis Daily each morning at 7 a.m.

FIRST DRAFT

Washington State have approved draft social equity licensing rules

The Washington State Liquor and Cannabis Board approved draft social equity licensing rules for cannabis licensees on August 3 that would add section “570 Social Equity in Cannabis Program” to Washington Annotated Code (“WAC”) Title 314-55. , via Lexology.

The rule is aimed at granting retail cannabis licensing opportunities to people who have been disproportionately affected by the War on Drugs, and could go into effect as early as September 28. 

Harris Bricken at Lexology’s Canna Law Blog discusses his concern that, if unchanged, parts of the rule are likely to harm the very people it is intended to benefit.


NOT THE FULL PICTURE

Did wholesale cannabis disruptions impact Canada’s cannabis market?

Service disruptions at two of Canada’s biggest government-run cannabis wholesalers in August do not appear to have meaningfully impacted the broader market, interim data for the month suggests, per MJBiz Daily.

However, some say the evident top-line growth doesn’t paint a full picture of potential sales had there been no disruptions. 

Nor does it account for consumers who returned – some permanently – to the illicit market or stores that could close for good in the coming months because of unreliable wholesalers.

⏰ Pre-order discount ends Jan 15
-- Days
-- Hours
-- Mins
Data packs delivered January 2026
🔬 New Report Due January 2026

Global Medical Cannabis Market Review 2026

A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.

What's covered

  • 📊 Global supply chain overview — understand export/import dynamics and domestic production capabilities
  • 🌍 8 export country snapshots — Canada, Portugal, Denmark, North Macedonia, Spain, Australia, Czech Republic, South Africa
  • 👥 6 patient market snapshots — Australia, Germany, UK, Poland, Brazil, France
  • 🔮 Key themes — Canada's global impact, telemedicine growth, new market openings, quota changes
Export Markets
🇨🇦 Canada 🇵🇹 Portugal 🇩🇰 Denmark 🇲🇰 N. Macedonia 🇪🇸 Spain 🇦🇺 Australia 🇨🇿 Czechia 🇿🇦 South Africa
Patient Markets
🇦🇺 Australia 🇩🇪 Germany 🇬🇧 UK 🇵🇱 Poland 🇧🇷 Brazil 🇫🇷 France
100% free • No credit card required
As trusted by
DIAGEO KPMG Coca-Cola BARCLAYS BNP PARIBAS AB InBev NOVARTIS Johnson & Johnson PEPSICO AXA POLITICO Bloomberg amazon CNN Business
Part of our annual market review series GDPR compliant

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?